Thomas O Krag

List of Publications by Year
in descending order

87	2,935	304602 22	168321 53
papers	citations	h-index	g-index

88	88	88	3417
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Functional improvement of dystrophic muscle by myostatin blockade. Nature, 2002, 420, 418-421.	13.7	748
2	90-kDa Ribosomal S6 Kinase Is Phosphorylated and Activated by 3-Phosphoinositide-dependent Protein Kinase-1. Journal of Biological Chemistry, 1999, 274, 27168-27176.	1.6	220
3	Myostatin propeptideâ€mediated amelioration of dystrophic pathophysiology. FASEB Journal, 2005, 19, 543-549.	0.2	219
4	Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain, 2006, 129, 3402-3412.	3.7	184
5	Heregulin ameliorates the dystrophic phenotype in mdx mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13856-13860.	3.3	112
6	Activation of Utrophin Promoter by Heregulin via theets-related Transcription Factor Complex GA-binding Protein Î±/Î². Molecular Biology of the Cell, 1999, 10, 2075-2086.	0.9	104
7	Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain, 2008, 131, 2824-2831.	3.7	100
8	Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. Journal of Molecular Medicine, 2004, 82, 102-115.	1.7	91
9	Endurance training: An effective and safe treatment for patients with LGMD2I. Neurology, 2007, 68, 59-61.	1.5	79
10	Characterization of a glutathione S-transferase and a related glutathione-binding protein from gill of the blue mussel, Mytilus edulis. Biochemical Journal, 1995, 305, 145-150.	1.7	72
11	Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes, phenotypes, cardiac findings, and muscle protein expression. Journal of Neurology, 2013, 260, 2084-2093.	1.8	63
12	Calpain 3 is important for muscle regeneration: Evidence from patients with limb girdle muscular dystrophies. BMC Musculoskeletal Disorders, 2012, 13, 43.	0.8	49
13	IL-6 release from muscles during exercise is stimulated by lactate-dependent protease activity. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E940-E947.	1.8	48
14	Shortâ€and longâ€term effects of endurance training in patients with mitochondrial myopathy. European Journal of Neurology, 2009, 16, 1336-1339.	1.7	44
15	Resistance training in patients with limbâ€girdle and becker muscular dystrophies. Muscle and Nerve, 2013, 47, 163-169.	1.0	43
16	Effect of sildenafil on skeletal and cardiac muscle in <scp>B</scp>ecker muscular dystrophy. Annals of Neurology, 2014, 76, 550-557.	2.8	39
17	Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy. Mitochondrion, 2020, 50, 35-41.	1.6	38
18	Deletion of exon 16 of the dystrophin gene is not associated with disease. Human Mutation, 2007, 28, 205-205.	1.1	29

#	Article	IF	Citations
19	Muscle involvement in limb-girdle muscular dystrophy with GMPPB deficiency (LGMD2T). Neurology: Genetics, 2016, 2, e112.	0.9	29
20	POPDC3 Gene Variants Associate with a New Form of Limb Girdle Muscular Dystrophy. Annals of Neurology, 2019, 86, 832-843.	2.8	27
21	Nampt controls skeletal muscle development by maintaining Ca2+ homeostasis and mitochondrial integrity. Molecular Metabolism, 2021, 53, 101271.	3.0	27
22	Level of muscle regeneration in limb-girdle muscular dystrophy type 2I relates to genotype and clinical severity. Skeletal Muscle, 2011, 1, 31.	1.9	26
23	Differential Muscle Involvement in Mice and Humans Affected by McArdle Disease. Journal of Neuropathology and Experimental Neurology, 2016, 75, 441-454.	0.9	24
24	Sp1 and the ets-related transcription factor complex GABPÎ±/Î² functionally cooperate to activate the utrophin promoter. Journal of the Neurological Sciences, 2002, 197, 27-35.	0.3	23
25	Muscle Atrophy Reversed by Growth Factor Activation of Satellite Cells in a Mouse Muscle Atrophy Model. PLoS ONE, 2014, 9, e100594.	1.1	22
26	Limb girdle muscular dystrophy due to mutations in POMT2. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 506-512.	0.9	21
27	Harnessing the potential of dystrophin-related proteins for ameliorating Duchenneâ€™s muscular dystrophy. Acta Physiologica Scandinavica, 2001, 171, 349-358.	2.3	20
28	Adaptations in Mitochondrial Enzymatic Activity Occurs Independent of Genomic Dosage in Response to Aerobic Exercise Training and Deconditioning in Human Skeletal Muscle. Cells, 2019, 8, 237.	1.8	20
29	Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success. Cells, 2021, 10, 533.	1.8	19
30	A New Mouse Model of Limb-Girdle Muscular Dystrophy Type 2I Homozygous for the Common L276I Mutation Mimicking the Mild Phenotype in Humans. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1137-1146.	0.9	18
31	No muscle involvement in myoclonusâ€dystonia caused by Ɛâ€sarcoglycan gene mutations. European Journal of Neurology, 2008, 15, 525-529.	1.7	17
32	Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment. Acta Neuropathologica Communications, 2019, 7, 167.	2.4	17
33	Glycogen Synthesis in Glycogenin 1â€“Deficient Patients: A Role for Glycogenin 2 in Muscle. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2690-2700.	1.8	16
34	Effect of Aerobic Exercise Training and Deconditioning on Oxidative Capacity and Muscle Mitochondrial Enzyme Machinery in Young and Elderly Individuals. Journal of Clinical Medicine, 2020, 9, 3113.	1.0	16
35	Identification of genes that are differentially expressed in extraocular and limb muscle. Journal of the Neurological Sciences, 2000, 179, 76-84.	0.3	15
36	Heregulinâ€induced epigenetic regulation of the utrophinâ€A promoter. FEBS Letters, 2007, 581, 4153-4158.	1.3	15

#	Article	IF	Citations
37	Muscle regeneration and inflammation in patients with facioscapulohumeral muscular dystrophy. Acta Neurologica Scandinavica, 2013, 128, 194-201.	1.0	15
38	A pilot study of muscle plasma protein changes after exercise. Muscle and Nerve, 2014, 49, 261-266.	1.0	15
39	Protein-carbohydrate supplements improve muscle protein balance in muscular dystrophy patients after endurance exercise: a placebo-controlled crossover study. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 308, R123-R130.	0.9	15
40	A single c.1715G>C calpain 3 gene variant causes dominant calpainopathy with loss of calpain 3 expression and activity. Human Mutation, 2020, 41, 1507-1513.	1.1	15
41	Phenotype and clinical course in a family with a new de novo Twinkle gene mutation. Neuromuscular Disorders, 2008, 18, 306-309.	0.3	13
42	A novel de novo mutation of the mitochondrial tRNAlys gene mt.8340G>A associated with pure myopathy. Neuromuscular Disorders, 2014, 24, 162-166.	0.3	13
43	Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. BMC Neurology, 2019, 19, 247.	0.8	13
44	Preclinical Research in Glycogen Storage Diseases: A Comprehensive Review of Current Animal Models. International Journal of Molecular Sciences, 2020, 21, 9621.	1.8	13
45	Clinical heterogeneity and phenotype/genotype findings in 5 families with <i>GYG1</i> deficiency. Neurology: Genetics, 2017, 3, e208.	0.9	12
46	Differential glucose metabolism in mice and humans affected by McArdle disease. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 311, R307-R314.	0.9	11
47	Collagen XII myopathy with rectus femoris atrophy and collagen XII retention in fibroblasts. Muscle and Nerve, 2018, 57, 1026-1030.	1.0	11
48	BAG3 myopathy is not always associated with cardiomyopathy. Neuromuscular Disorders, 2018, 28, 798-801.	0.3	11
49	Low survival rate and muscle fiber-dependent aging effects in the McArdle disease mouse model. Scientific Reports, 2019, 9, 5116.	1.6	11
50	Electroporation Enhanced Effect of Dystrophin Splice Switching PNA Oligomers in Normal and Dystrophic Muscle. Molecular Therapy - Nucleic Acids, 2015, 4, e267.	2.3	10
51	Preserved Capacity for Adaptations in Strength and Muscle Regulatory Factors in Elderly in Response to Resistance Exercise Training and Deconditioning. Journal of Clinical Medicine, 2020, 9, 2188.	1.0	10
52	Depletion of ATP Limits Membrane Excitability of Skeletal Muscle by Increasing Both ClC1-Open Probability and Membrane Conductance. Frontiers in Neurology, 2020, 11, 541.	1.1	9
53	Expanding the phenotype of filamin-C-related myofibrillar myopathy. Clinical Neurology and Neurosurgery, 2019, 176, 30-33.	0.6	8
54	A new mutation of the fukutin gene causing late-onset limb girdle muscular dystrophy. Neuromuscular Disorders, 2013, 23, 562-567.	0.3	7

#	Article	IF	Citations
55	Protein Turnover and Cellular Stress in Mildly and Severely Affected Muscles from Patients with Limb Girdle Muscular Dystrophy Type 2I. PLoS ONE, 2013, 8, e66929.	1.1	7
56	Approaches for Systemic Delivery of Dystrophin Antisense Peptide Nucleic Acid in the mdx Mouse Model. Nucleic Acid Therapeutics, 2021, 31, 208-219.	2.0	7
57	Muscle regeneration in mitochondrial myopathies. Mitochondrion, 2013, 13, 63-70.	1.6	6
58	Muscle biopsy and <scp>MRI</scp> findings in <scp>ANO5</scp>â€related myopathy. Muscle and Nerve, 2021, 64, 743-748.	1.0	6
59	Exercising with blocked muscle glycogenolysis: Adaptation in the McArdle mouse. Molecular Genetics and Metabolism, 2018, 123, 21-27.	0.5	5
60	Absence of p.R50X Pygm read-through in McArdle disease cellular models. DMM Disease Models and Mechanisms, 2019, 13, .	1.2	4
61	No effect of oral sucrose or IV glucose during exercise in phosphorylase b kinase deficiency. Neuromuscular Disorders, 2020, 30, 340-345.	0.3	4
62	251st ENMC international workshop: Polyglucosan storage myopathies 13â€“15 December 2019, Hoofddorp, the Netherlands. Neuromuscular Disorders, 2021, 31, 466-477.	0.3	4
63	No effect of resveratrol in patients with mitochondrial myopathy: A crossâ€over randomized controlled trial. Journal of Inherited Metabolic Disease, 2021, 44, 1186-1198.	1.7	4
64	Preclinical Research in McArdle Disease: A Review of Research Models and Therapeutic Strategies. Genes, 2022, 13, 74.	1.0	4
65	A New Mouse Model of Limb-Girdle Muscular Dystrophy Type 2I Homozygous for the Common L276I Mutation Mimicking the Mild Phenotype in Humans. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1137-1146.	0.9	3
66	Results of an open label feasibility study of sodium valproate in people with McArdle disease. Neuromuscular Disorders, 2020, 30, 734-741.	0.3	3
67	Myopathy can be a key phenotype of membrin (GOSR2) deficiency. Human Mutation, 2021, 42, 1101-1106.	1.1	3
68	Vacuoles, Often Containing Glycogen, Are a Consistent Finding in Hypokalemic Periodic Paralysis. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1127-1129.	0.9	2
69	Autophagy is affected in patients with hypokalemic periodic paralysis: an involvement in vacuolar myopathy?. Acta Neuropathologica Communications, 2021, 9, 109.	2.4	2
70	Extreme Hypoxia Causing Brady-Arrythmias During Apnea in Elite Breath-Hold Divers. Frontiers in Physiology, 2021, 12, 712573.	1.3	2
71	Three novel FHL1 variants cause a mild phenotype of Emeryâ€Dreifuss muscular dystrophy. Human Mutation, 2022, 43, 1234-1238.	1.1	2
72	Muscle biopsies off-set normal cellular signaling in surrounding musculature. Neuromuscular Disorders, 2013, 23, 981-985.	0.3	1

#	Article	IF	Citations
73	A possible role of MAP-1 in skeletal muscle regeneration. Immunobiology, 2012, 217, 1130.	0.8	0
74	G.P.42 Protein turnover and cellular stress in mildly and severely affected muscles from patients with limb girdle muscular dystrophy type 2I. Neuromuscular Disorders, 2012, 22, 832.	0.3	0
75	T.P.36 Hepatocyte growth factor reverses atrophy by inducing protein synthesis in mice. Neuromuscular Disorders, 2012, 22, 863.	0.3	0
76	P.8.12 Mild phenotype in a Limb Girdle muscular dystrophy type 2I mouse model homozygous for the common L276I mutation. Neuromuscular Disorders, 2013, 23, 783.	0.3	0
77	Molecular, morphological and physiological studies in a mouse model of McArdle disease: Similarities to the human disease. Neuromuscular Disorders, 2015, 25, S219.	0.3	0
78	Effect of treatment with grow factors on muscle pathology in the mdx mouse model of Duchenne muscular dystrophy. Neuromuscular Disorders, 2015, 25, S291.	0.3	0
79	New advances in McArdle disease: Characterization of the p.R50X knock-in mouse model and evaluation of new therapeutic approaches. Neuromuscular Disorders, 2016, 26, S199.	0.3	0
80	DMD TREATMENT: ANIMAL MODELS. Neuromuscular Disorders, 2018, 28, S96.	0.3	0
81	O.14B3GNT4 deficiency: a new Î±-dystroglycanopathy causing late-onset progressive brain atrophy and muscular dystrophy. Neuromuscular Disorders, 2019, 29, S118-S119.	0.3	0
82	P.119Analysis of the structural and metabolic consequences of McArdle disease using the murine model. Neuromuscular Disorders, 2019, 29, S83.	0.3	0
83	MYASTHENIA & RELATED DISORDERS. Neuromuscular Disorders, 2020, 30, S58.	0.3	0
84	MUSCLE FUNCTION & HOMEOSTASIS / MOLECULAR THERAPEUTIC APPROACHES. Neuromuscular Disorders, 2020, 30, S68.	0.3	0
85	LIMB GIRDLE MUSCULAR DYSTROPHIES. Neuromuscular Disorders, 2020, 30, S90.	0.3	0
86	Novel Homozygous Truncating Variant Widens the Spectrum of Early-Onset Multisystemic SYNE1 Ataxia. Cerebellum, 2021, , 1.	1.4	0
87	Growth Factors Do Not Improve Muscle Function in Young or Adult mdx Mice. Biomedicines, 2022, 10, 304.	1.4	0